Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Crescent Biopharma, Inc.NASDAQ: CBIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $64K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $148K. Over 3 fiscal years it compounded at -26.0% a year.
Context
- Depreciation & amortization amounted to 0.8% of revenue in FY2025.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly depreciation & amortization holds near $64K or moves back toward the trailing-twelve-month quarterly average of $37K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 84K USD
- Year-over-year change
- +138.8%
- 4-year CAGR
- -24.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84K | +138.8% |
| FY2024 | 2024-12-31 | 35.17K | -77.1% |
| FY2023 | 2023-12-31 | 153.3K | -26.0% |
| FY2022 | 2022-12-31 | 207.15K | -21.7% |
| FY2021 | 2021-12-31 | 264.6K | — |
Depreciation & Amortization vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -99.6% is the lowest of 9, against a peer median of -15.7%.
- Depreciation & amortization amounts to 1.2% of revenue for CBIO, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Sep 2026 | $8.21M USD | -35.8% | -2.5% | 3.1% | |
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| LTM Sep 2026 | $3.73M USD | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $1.24M USD | -26.3% | -17.4% | 3.5% | |
| LTM Mar 2026 | $1.12M USD | -32.0% | -8.2% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥1.03M CNY | -95.7% | -55.8% | — |
| LTM Mar 2026 | $148K USD | -99.6% | -26.0% | 1.2% | |
| LTM Mar 2026 | $48.3K USD | +290.5% | +20.6% | — | |
| LTM Mar 2026 | $0 USD | — | -0.5% | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | -15.7% | -2.5% | 4.0% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| Weighted Avg Shares | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
| Weighted Avg Shares (Diluted) | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.